text
"[""\n1. 요약재무정보\n가. 요약연결재무정보\n\xa0 \xa0 \xa0 ( 단위 : 천원 )\n구분\n제 51 기\n제 50 기\n제 49 \xa0기\n연결재무상태표\n2021. 12월말\n2020. 12월말\n2019. 12월말\n\xa0[유동자산]\n76,863,062\n20,426,044\n156,392,087\n\xa0ㆍ현금및현금성자산\n9,186,408\n2,421,594\n19,127,037\n\xa0ㆍ단기금융상품\n91,943\n-\n506,746\n\xa0ㆍ매출채권\n20,859,343\n14,487,472\n39,224,535\n\xa0ㆍ기타자산\n4,405,358\n3,277,070\n60,226,286\n\xa0ㆍ매각예정비유동자산\n39,906,534\n-\n27,000,000\n\xa0ㆍ재고자산\n2,413,475\n239,908\n10,307,483\n\xa0[비유동자산]\n39,563,751\n48,170,596\n217,480,637\n\xa0ㆍ금융자산\n3,412,954\n2,466,679\n5,408,834\n\xa0ㆍ종속기업및관계기업투자\n-\n42,868,381\n1,332,670\n\xa0ㆍ유형자산\n19,622,969\n71,965\n194,477,649\n\xa0ㆍ사용권자산\n1,930,936\n908,620\n1,965,985\n\xa0ㆍ무형자산\n11,204,427\n726,936\n6,141,470\n\xa0ㆍ장기매출채권\n133,463\n218,609\n550,000\n\xa0ㆍ기타자산\n3,259,002\n909,406\n7,604,029\n자 \xa0산 \xa0총 \xa0계\n116,426,813\n68,596,640\n373,872,724\n\xa0[유동부채]\n65,942,789\n45,070,943\n146,131,910\n\xa0[비유동부채]\n5,943,255\n3,851,122\n72,429,838\n부 채 총 계\n71,886,044\n48,922,065\n218,561,748\n\xa0[지배기업 소유지지분]\n31,144,703\n19,674,575\n24,871,939\n\xa0ㆍ자본금\n15,560,554\n12,508,293\n12,508,293\n\xa0ㆍ자본잉여금\n53,286,363\n35,270,580\n35,081,035\n\xa0ㆍ기타자본항목\n1,428,920\n1,428,920\n1,535,326\n\xa0ㆍ기타포괄손익누계액\n(4,007,401)\n(1,635,666)\n17,510,367\n\xa0ㆍ이익잉여금\n(35,123,732)\n(27,897,552)\n(41,763,082)\n\xa0[비지배지분]\n13,396,065\n-\n130,439,037\n자 본 총 계\n44,540,769\n19,674,575\n155,310,976\n관계기업 투자주식의 평가방법\n지분법\n지분법\n지분법\n연결손익계산서\n'21.01.01~12.31\n'20.01.01~12.31\n'19.01.01~12.31\n\xa0매출액\n75,724,705\n72,469,645\n58,736,694\n\xa0영업손익\n(6,633,228)\n(1,999,554)\n1,013,792\n\xa0연결계속영업당기순이익\n(7,010,942)\n(10,311,445)\n(9,772,257)\nㆍ지배기업소유주지분손익\n(7,180,518)\n(10,311,445)\n(9,772,257)\nㆍ비지배기업소유주지분손익\n169,576\n-\n-\n\xa0연결중단영업당기순이익\n(911,372)\n9,184,574\n5,395,995\n\xa0당기순손익\n(7,922,314)\n(1,126,871)\n(4,376,262)\n\xa0주당순손익(원)\n(265)\n(120)\n(14)\n\xa0연결에포함된회사수\n1개\n-\n4개\n※ 상기 요약 재무정보는 한국 채택국제회계기준(K-IFRS)에 따라 작성되었습니다.※ 2019년 1월 1일을 최초적용일로 하여 K-IFRS 제1116호를 최초 적용하였습니다.\n나. 연결재무제표의 연결에 포함된 회사\n종속기업명\n소유지분율\n소재지\n결산월\n업종\n셀론텍(주)\n51.0%\n한국\n12월\n바이오콜라겐 기반 치료재료 생산 및 판매\n다. 요약재무정보(별도)\n\xa0 \xa0 \xa0 ( 단위 : 천원 )\n구분\n제 51 기\n제 50 기\n제 49 \xa0기\n재무상태표\n2021. 12월말\n2020. 12월말\n2019. 12월말\n\xa0[유동자산]\n71,364,365\n20,426,044\n15,790,631\n\xa0ㆍ현금및현금성자산\n7,711,622\n2,421,593\n2,539,584\n\xa0ㆍ매출채권\n20,450,332\n14,487,472\n8,664,789\n\xa0ㆍ기타자산\n3,157,130\n3,277,071\n4,263,069\n\xa0ㆍ매각예정비유동자산\n39,906,534\n-\n-\n\xa0ㆍ재고자산\n138,747\n239,908\n323,189\n\xa0[비유동자산]\n28,233,309\n48,170,596\n57,687,859\n\xa0ㆍ금융자산\n3,412,954\n2,466,679\n2,432,544\n\xa0ㆍ종속기업및관계기업투자\n17,136,000\n42,868,381\n50,408,254\n\xa0ㆍ유형자산\n42,588\n71,965\n107,348\n\xa0ㆍ사용권자산\n265,543\n908,620\n1,021,572\n\xa0ㆍ무형자산\n5,734,757\n726,936\n774,143\n\xa0ㆍ장기매출채권\n133,463\n218,609\n550,000\n\xa0ㆍ기타자산\n1,508,004\n909,406\n2,393,998\n자 \xa0산 \xa0총 \xa0계\n99,597,674\n68,596,640\n73,478,490\n\xa0[유동부채]\n64,183,602\n45,070,943\n37,973,172\n\xa0[비유동부채]\n911,128\n3,851,122\n4,302,761\n부 채 총 계\n65,094,730\n48,922,065\n42,275,933\n\xa0ㆍ자본금\n15,560,554\n12,508,293\n12,508,294\n\xa0ㆍ자본잉여금\n51,132,267\n33,093,573\n33,086,584\n\xa0ㆍ기타포괄손익누계액\n(4,007,401)\n(1,635,666)\n200,482\n\xa0ㆍ이익잉여금\n(28,182,476)\n(24,291,625)\n(14,592,803)\n자 본 총 계\n34,502,944\n19,674,575\n31,202,557\n종속기업 투자주식의 평가방법\n원가법\n원가법\n원가법\n관계기업 투자주식의 평가방법\n지분법\n지분법\n지분법\n손익계산서\n'21.01.01~12.31\n'20.01.01~12.31\n'19.01.01~12.31\n\xa0매출액\n80,226,517\n72,469,645\n58,736,694\n\xa0영업손익\n(4,012,277)\n(1,999,555)\n1,013,792\n\xa0당기순손익\n(4,457,200)\n(10,136,416)\n(9,772,257)\n\xa0주당순손익(원)\n(155)\n(405)\n(391)\n※ 상기 요약 재무정보는 한국 채택국제회계기준(K-IFRS)에 따라 작성되었습니다.※ 2019년 1월 1일을 최초적용일로 하여 K-IFRS 제1116호를 최초 적용하였습니다.\n""]"
